Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.6
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 9 Months Ended
Apr. 30, 2013
Apr. 30, 2012
Apr. 30, 2013
Apr. 30, 2012
Revenues:        
Clinical laboratory services $ 13,384 $ 15,242 $ 41,881 $ 43,552
Product revenues 8,265 9,574 24,574 28,819
Royalty and license fee income 949 1,133 3,982 4,302
Total revenues 22,598 25,949 70,437 76,673
Operating expenses:        
Cost of clinical laboratory services 9,331 9,204 28,466 26,728
Cost of product revenues 4,219 4,689 12,546 14,511
Research and development 989 1,588 2,968 4,916
Selling, general, and administrative 11,032 11,854 33,340 35,727
Provision for uncollectible accounts receivable 928 1,193 3,857 3,648
Legal 1,708 943 4,850 2,835
Total operating expenses 28,207 29,471 86,027 88,365
Operating loss (5,609) (3,522) (15,590) (11,692)
Other income (expense):        
Interest (10) (18) (25) (6)
Other 25 15 81 94
Foreign currency income (loss) (214) 80 119 (243)
Loss before income taxes (5,808) (3,445) (15,415) (11,847)
Benefit (provision) for income taxes 38 34 280 (279)
Net loss $ (5,770) $ (3,411) $ (15,135) $ (12,126)
Net loss per common share:        
Basic and diluted (in Dollars per share) $ (0.15) $ (0.09) $ (0.38) $ (0.31)
Weighted average common shares outstanding:        
Basic and diluted (in Shares) 39,553 38,825 39,381 38,676